Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag plus recombinant human thrombopoietin in chronic liver disease-associated thrombocytopenia before elective invasive surgery
ChiCTR2500102121Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- May 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lusutrombopag and recombinant human thrombopoietin in Thrombocytopenia and chronic liver disease (CLD), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Percentage of responders at day 8. Planned start May 2025; status: not yet recruiting.
02
Drugs
lusutrombopagrecombinant human thrombopoietin
03
Conditions
Thrombocytopeniachronic liver disease (CLD)
Beyond the preview
Go deeper on ChiCTR2500102121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102121.